Verax Research Services

Verax Research Services is a private U.S. healthcare-focused research and product development company working at the intersection of rare disease drug development, hemp/CBD-related product research, and consulting services. The company presents itself as focused on orphan drug research and has publicly identified glioblastoma as its primary rare-disease development area, with an initial product branded GlioVite. Verax also describes broader capabilities spanning science, medicine, manufacturing, technology, education, sourcing, and business consulting. Publicly available information suggests the company is an early-stage, private organization rather than a clinically advanced biotech with a broad disclosed therapeutic pipeline. Its disclosed healthcare activities appear centered on rare-disease concept development, product research, and related service offerings.